Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05189327
Other study ID # KSSSID-052021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 10, 2021
Est. completion date December 31, 2024

Study information

Verified date December 2021
Source Kazakhstan Scientific Society for Study of intestine diseases
Contact Jamilya Kaibullayeva, PhD
Phone +77471051195
Email kaibullaev@mail.ru
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The NUCaCD study aims to develop a reliable registry of patients suffering inflammatory bowel diseases in the Republic of Kazakhstan.


Description:

The NUCaCD aims to study the prevalence of inflammatory bowel diseases in the Republic of Kazakhstan and create a reliable database, which will greatly facilitate future planning of the volume of health resources needed to address these diseases management and will help to optimize preventive measures and will support future research to better understand the etiology, new options treatment and factors affecting prognosis, relapses, development of complications and quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Availability of a signed informed consent form; or the presence of a disinterested witness if the patient is unable to examine and sign the consent form due to illiteracy or disability (for example, in the case of blindness); - The patient has a documented diagnosis of ulcerative colitis or Crohn's disease (endoscopy, histology, if indicated by radiation diagnostics); - Patients who have applied for treatment or are already taking treatment from a gastroenterologist / coloproctologist, including inpatients; - Citizenship of the Republic of Kazakhstan (or resides). Exclusion Criteria: - Patient takes part in an interventional clinical trial; - Patient is unable to follow the schedule of the visits; - Any condition that the PI believes would prevent a study participant from participating in the study.

Study Design


Intervention

Other:
No intervention
Non-interventional study

Locations

Country Name City State
Kazakhstan Primary Health Clinic #5 Almaty

Sponsors (2)

Lead Sponsor Collaborator
Kazakhstan Scientific Society for Study of intestine diseases FERRING Kazakhstan

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type Measure Description Time frame Safety issue
Primary To study the incidence of NUC and CD in the Republic of Kazakhstan To study the incidence of NUC and CD in the Republic of Kazakhstan 2 years
Secondary To study the patterns of the course of the disease and the treatment effect To study the patterns of the course of the disease and the effectiveness of drug therapy in outpatient and inpatient clinics. 2 years
Secondary Conduct an analysis of the completeness of the diagnosis and compliance with the national guidelines for the diagnosis and treatment of ulcerative colitis and Crohn's disease Conduct an analysis of the completeness of the diagnosis and compliance with the national guidelines for the diagnosis and treatment of ulcerative colitis and Crohn's disease 2 years
Secondary Analysis of the relationship between management strategies and treatment outcomes Analysis of the relationship between management strategies and treatment outcomes 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05519904 - Prevalence of Encephalopathy in Patients With Inflammatory Bowel Diseases
Recruiting NCT04844606 - A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) Phase 3
Recruiting NCT05767021 - A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis Phase 3
Recruiting NCT04148274 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Ulcerative Colitis
Not yet recruiting NCT05341401 - Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05666960 - R-3750 in Patients With Mild to Moderate Ulcerative Colitis Phase 1
Recruiting NCT04695964 - Objective Perfusion Rate Assessment by Near-infrared Fluorescence in Ileal Pouch Formation and Ileal-pouch-anal Anastomosis N/A
Withdrawn NCT05578508 - Stem Cells for the Treatment of Pouchitis Phase 1